Chengdu, China – October 31, 2025 – Maxvax Biotechnology Co., Ltd. (“Maxvax”) today announced the successful completion of its Series D financing round, raising over RMB 400 million.

This round was jointly invested by IDG Capital, Shenzhen Capital Group (SCGC), and Ruipu Pharma. The funds will primarily support the clinical trials and commercialization preparation of Maxvax’s recombinant shingles (herpes zoster) vaccine, the Phase III clinical trial of its recombinant respiratory syncytial virus (RSV) vaccine, and preclinical research for multiple innovative vaccine candidates and international collaborations.

Dr. Dexiang Chen, Founder and CEO of Maxvax, commented:

“We are deeply grateful to IDG Capital, SCGC, and our existing investors for their continued trust and support, and we warmly welcome Ruipu Pharma as a new shareholder. The funds raised in this round will further strengthen our R&D capabilities and accelerate the clinical development and commercialization of our shingles and RSV vaccines. We aim to achieve commercialization of these vaccines within the next two years and contribute to advancing global public health.”

About Maxvax

Guided by the values of “Integrity, Innovation, Collaboration, and Global Service,” Maxvax Biotech is committed to addressing global public health challenges and providing effective solutions for the prevention and control of major infectious and chronic diseases.

Leveraging its cutting-edge R&D capabilities and rapidly expanding commercial manufacturing capacity, Maxvax has grown rapidly and has now completed its Series D financing, with cumulative funding exceeding RMB 2 billion.

The company focuses on the research, development, manufacturing, and commercialization of innovative human and veterinary (including companion animal) vaccines. Built upon its proprietary adjuvant, recombinant protein, and immune evaluation platforms, Maxvax has established a robust pipeline of major innovative vaccine candidates.

Maxvax has developed nearly 20 adjuvant raw materials, three mature delivery systems, and over 10 composite formulations, forming a vertically integrated value chain that spans from adjuvant R&D and manufacturing to formulation development and application.

The company’s diversified vaccine portfolio targets infectious diseases, allergic diseases, and cancers, encompassing both prophylactic vaccines against major infectious diseases and therapeutic vaccines for HPV infection, allergic disorders, and oncology.
To advance the industrialization of novel adjuvants and human vaccines, Maxvax has also established an innovative vaccine technology transfer platform and initiated the construction of a commercial-scale production base.